BCRX: Summary for BioCryst Pharmaceuticals, Inc. - Yahoo Finance

UK Markets open in 7 hrs 20 mins

BioCryst Pharmaceuticals, Inc. (BCRX)


NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
6.51-0.10 (-1.51%)
At close: 4:00PM EDT
People also watch
NVAXHEBVICLARRYALNY
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous close6.61
Open6.57
Bid6.21 x 100
Ask7.44 x 700
Day's range6.37 - 6.66
52-week range2.49 - 9.25
Volume674,341
Avg. volume1,712,773
Market cap523.26M
Beta2.78
PE ratio (TTM)-8.70
EPS (TTM)N/A
Earnings dateN/A
Dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
Trade prices are not sourced from all markets
  • American City Business Journals10 days ago

    After announcing a $45M public offering, BioCryst to launch new trial

    On the heels of announcing a $45 million secondary public offering of the company’s common stock last month, Durham-based BioCryst Pharmaceuticals (BCRX) plans to move forward with a new trial for its hereditary angioedema (HAE) therapy BCX7353. The company said it will explore a new oral liquid for treating acute attacks in patients with hereditary angioedema. It added that it has received “initial regulatory approvals in Europe” for the clinical trial.

  • GlobeNewswire12 days ago

    BioCryst Expands Development of BCX7353 to Explore Treatment of Acute HAE Attacks

    RESEARCH TRIANGLE PARK, N.C., April 12, 2017-- BioCryst Pharmaceuticals, Inc., a pharmaceutical company focused on the development and commercialization of treatments for rare diseases, announced today ...

  • American City Business Journals19 days ago

    BioCryst to receive royalties from cancer treatment approved in Japan

    Durham-based BioCryst Pharmaceuticals (BCRX) stands to receive royalties from a new cancer therapy approved in Japan. The company announced that Mundipharma – with which it has a sub-licensing agreement – has received approval from the the Ministry of Health, Labor and Welfare in Japan for Mundesine, a therapy for the treatment of Peripheral T-Cell Lymphoma. “Under the terms of the agreement with Mundipharma, BioCryst will receive tiered royalties ranging from the mid- to high-single digit percentages of net sales of Mundesine,” BioCryst stated.